AMAlejandra Molano-Triviño

Alejandra Molano-Triviño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alejandra Molano-Triviño has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peritoneal–Mediastinal Dialysate Leak Presenting as Chest Pain in a Patient on Peritoneal Dialysis

    by Alejandra Molano Triviño, Diego Piñeros, Juan Camilo Castellanos De la Hoz, Eduardo Zúñiga Rodríguez, Laura Caro

    Peritoneal dialysis (PD)–related leaks are usually pleuroperitoneal; mediastinal extension is exceptionally rare. A 38-year-old man with ESKD due to immune complex–mediated focal segmental glomerulosclerosis on long-term automated PD presented with acute exertional chest pain mimicking an acute coronary syndrome. Cardiac biomarkers were elevated, but electrocardiography and coronary angiography showed no ischemic disease. Computed tomography pulmonary angiography excluded pulmonary embolism and revealed a paraesophageal fluid collection. Contrast-enhanced computed tomography after intraperitoneal instillation of iodinated dialysate confirmed mediastinal leakage through the esophageal hiatus. Increased intra-abdominal pressure and an umbilical hernia were identified as risk factors. PD withdrawal and transition to hemodialysis led to complete resolution. Mediastinal dialysate leakage should be considered in PD patients with unexplained chest pain; computed tomography peritoneography is diagnostic.

  • Open Access

    From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor

    by Juan Castellanos-De la Hoz, Alejandra Molano-Triviño, Yesid Felipe González-García, Lina Maria Espinosa Saltaren, Eduardo Zúñiga-Rodríguez

    Osmotic nephropathy is an infrequent drug‑induced complication characterized by vacuolization of renal tubular cells secondary to lysosomal uptake, w


  • Extracorporeal Blood Purification Therapies in Latin America: Bridging Gaps in Availability and Training

    by Lilia Rizo-Topete, Alejandra Molano-Triviño, Olynka Vega-Vega, Darío Jiménez, Alejandro Ferreiro, David Ballesteros, Daniela Ponce, Gonzalo Ramírez-Guerrero, Javier A. Neyra, Jonathan S. Chávez-Iñíguez, et al.

    Introduction: Socioeconomic and developmental diversity across Latin America (LA) significantly affects the availability of extracorporeal blood purification (EBP) therapies to treat acute kidney injury (AKI) and the training of nephrology fellows in these technologies. This survey assessed the availability of EBP therapies and perceived training needs of nephrologists and intensivists in the region. Objective: The aim of this study was to evaluate the availability of EBP therapies to treat AKI and identify training needs among LA nephrologists and intensivists. Methods: Between March and December 2024, the AKI and extracorporeal organ support therapy committee of SLANH conducted an online survey targeting nephrologists and intensivists. The survey gathered data on the availability of EBP technologies in their institutions and perceived training needs. Results: A total of 505 responses were collected, with 93% submitted by nephrologists. Participants represented 20 LA countries, primarily from South America (58%), Mexico (23.6%), and the Caribbean (10.1%). Intermittent hemodialysis (IHD) was the most widely available therapy, accessible in 98% of centers. Peritoneal dialysis (PD) was available in 65% of hospitals, while continuous renal replacement therapy (CRRT) in 59% of centers but reported as unavailable in Haiti, Nicaragua, Paraguay, and Venezuela. Therapeutic plasma exchange (TPE) was available in 60% of hospitals, although accessibility varied significantly by country. Multi-organ support therapies showed limited regional availability, including liver support (11.9%), extracorporeal membrane oxygenation (ECMO, 16.7%), extracorporeal CO2 removal (ECCO2R, 7%), and hemoadsorption (20.6%). The greatest perceived training needs were identified for ECMO (54.2%), ECCO2R (51.3%), CRRT (48.7%), and TPE (46.8%), whereas demand for further training in IHD and PD was comparatively lower. These findings underscore substantial disparities in therapy access and highlight urgent regional priorities for advanced EBP training. Conclusion: This study highlights significant disparities in EBP therapy availability across LA, with advanced modalities such as CRRT and multi-organ support largely inaccessible in several countries. Additionally, there is a high perceived need for training in ECMO, ECCO2R, CRRT, and TPE. Addressing these gaps requires expanding access to EBP, implementing standardized training programs, establishing regional centers of excellence, and fostering international collaboration. Policy advocacy and increased resource allocation will be essential to improving access and optimizing patient outcomes across the region.


  • Open Access

    Toward Green Dialysis: Efficacy and Sustainability with Reduced Dialysate Flow in Expanded Hemodialysis

    by Carolina Ramos, Juan Felipe Gutiérrez, Rafael M. Sanabria, Jasmin Vesga, Juan Castellanos De la Hoz, Eduardo Zuniga-Rodriguez, Alejandra Molano-Triviño

    Introduction: Reducing dialysate flow (Qd) to 400 mL/min has proven to be sufficient, safe, and effective in meeting dialysis adequacy requirements in adults, with the added advantage of decreasing water consumption per dialysis session. Expanded hemodialysis (HDx), which uses dialyzers with membranes capable of enhanced clearance of medium-sized molecules due to expanded pore capacity, has higher efficiency and reduces the importance of the dialysate-to-blood flow ratio (Qd/Qb) for molecule removal. The objective of this study was to evaluate dialysis effectiveness by analyzing the reduction rate of medium-sized molecules in patients weighing ≤70 kg, comparing Qd 400 mL/min vs. 500 mL/min in HDx using Theranova® membrane. Methods: A post hoc analysis of the COREXH study population was performed. This observational, analytical, retrospective cohort study included 23 patients, of whom 11 (47%) had Qd 400 mL/min and 12 (52.1%) had Qd 500 mL/min. Results: No statistically significant differences were observed in the reduction rate of medium-sized molecules between the Qd 400 mL/min and 500 mL/min groups. Additionally, water consumption was lower in the Qd 400 mL/min group, with an average saving of 24 L per patient per session and 13,824 L over 12 weeks. Conclusion: Using Qd 400 mL/min in HDx vs. 500 mL/min did not affect dialysis effectiveness in terms of molecule reduction rates and resulted in substantial water savings in Qd 400 mL/min group.


  • Therapeutic plasma exchange without anticoagulation: Single‐center experience

    by Eduardo Zúñiga‐Rodríguez, Danna Peña, Juliana Mantilla, Juan Camilo Castellanos‐De La Hoz, Maria Patricia Carvajal‐Abril, Isabel Cristina Saravia Bermeo, Alejandra Molano‐Triviño

    Background: Membrane therapeutic plasma exchange (mTPE) is indicated for treating autoimmune, neurological, hematological, and renal diseases. Few studies have assessed the effectiveness and safety of this technique, especially when no anticoagulants are added. This study evaluated the outcomes of mTPE without anticoagulation at a single center.Methods: Based on registry data, this retrospective cohort study included adult patients treated with mTPE without anticoagulants for different indications.Results: From October 2021 to October 2022, 46 patients received 385 mTPE treatments. The primary diagnosis leading to the intervention was humoral rejection of the kidney transplant (59.2%). Most procedures (62.1%) were performed in the inpatient department. The complication rate was 1.3%, with 2.1% of patients experiencing device coagulation. Only five patients experienced mild adverse events. There were no cases of mortality.Conclusions: When indicated, mTPE without anticoagulation is a safe hospital technique. Protocols are needed to guide the use and monitoring of this therapy.

  • Open Access

    Estado del arte del síndrome cardiorrenal, ventajas y limitaciones de las terapias conocidas

    by María Carolina Manzur Barbur, Ana Milena Mejía-Sanjuanelo, Marco Anaya-Taboada, Juan C García-Domínguez, Alejandra Molano- Triviño

    Las interacciones entre las enfermedades cardíacas y renales se han clasificado como síndromes cardiorenales. La clasificación actual incluye cinco subtipos, los cuales son: insuficiencia cardíaca aguda que conduce a insuficiencia renal aguda (tipo 1), insuficiencia cardíaca crónica que conduce a insuficiencia renal (tipo 2), lesión renal aguda que conduce a insuficiencia cardíaca (tipo 3), enfermedad renal crónica que conduce a insuficiencia cardíaca (tipo 4) y afecciones sistémicas que conducen a insuficiencia cardíaca y renal (tipo 5) (Tabla 1) (1,2). En esta revisión discutimos la definición, clasificación, fisiopatología del síndrome cardiorrenal, enfocándonos en el manejo en fases agudas y su recuperación, exponiendo la evidencia actualmente disponible de los diuréticos y la ultrafiltración con el objetivo de intervenir de manera oportuna a nuestros pacientes conociendo las ventajas y limitaciones de cada una de las estrategias de manejo en aras de reducir el riesgo de eventos clínicos, re- hospitalización y muerte.


  • Open Access

    Diálisis Peritoneal en tiempos difíciles.

    by José Mauricio Uribe Betancur, Alejandra Patricia Molano Triviño

    La Diálisis Peritoneal es una terapia igual o superior a la hemodiálisis, es costo-efectiva y ha permitido el soporte dialítico vital a poblaciones víctimas de desastres naturales. En las actuales circunstancias de pandemia y aislamiento social por el COVID 19, la diálisis peritoneal, al ser una terapia domiciliaria, reduce los riesgo de exposición para pacientes, cuidadores y equipos de atención, sin embargo, es una terapia subutilizada a nivel global. Al mostrar los beneficios de la diálisis peritoneal sobre la hemodiálisis y los desenlaces de esta en tiempos de desastre, se presenta como la mejor alternativa para estos tiempos de pandemia. Se llevó a cabo una revisión no sistemática de la literatura, en busca de los beneficios de la diálisis peritoneal vs hemodiálisis y sus desenlaces en situaciones de calamidad. En esta se incluyeron 75 artículos publicados entre1993 y marzo del 2020. Estos estudios muestran los múltiples beneficios de la diálisis peritoneal sobre la hemodiálisis y ser la mejor alternativa en situaciones de desastre. Por lo anterior concluimos que la diálisis peritoneal tiene significativos beneficios sobre la hemodiálisis, entre estos una mayor supervivencia, especialmente en los dos primeros años, una menor velocidad en la tasa de perdida de la función renal residual, permite preservar los accesos vasculares, hay mayor supervivencia post trasplante, además de ser más económica y en situaciones de desastres naturales, como lo es esta pandemia, ha facilitado la continuidad de la atención y el soporte dialítico agudo o crónico para las víctimas.

  • Open Access

    Hiperamonemia como causa de diálisis no renal

    by Benjamín Wancjer Nelds, Alejandra Molano Triviño, Samuel Yucuma Gutiérrez, Carlos Mauricio Martínez Montalvo

    La hiperamonemia es una condición frecuente en pacientes cirróticos y en el contexto de una causa no cirrótica se relaciona con aumento en la producción de amonio o alteración en su eliminación. La presentación clínica de esta condición es inespecífica: va desde alteración del comportamiento hasta estado de coma, siendo una de las causas de diálisis no renal por determinados valores o refractariedad a manejo médico. Se presenta el caso de una mujer de 35 años, quien ingresó al servicio de urgencias con alteración del estado de conciencia, niveles de amonio elevados y masa hipervascular en hígado. Los estudios de aminoácidos limitantes del ciclo de la urea y ácido orótico urinario fueron normales y la biopsia de la lesión hepática reportó carcinoma hepático fibrolamelar, al cual se atribuyó la presencia de shunt portosistémico que causaba la hiperamonemia. Se indicó diálisis por persistencia de elevaciones de amonio y poca respuesta al tratamiento médico. Dada la evolución de la paciente, fue necesario reiniciar la terapia reemplazo renal por reaparición de estado encefalopático al suspender la misma. Esta terapia se mantuvo hasta el trasplante hepático que se realizó como tratamiento del carcinoma, con posterior estabilización de niveles de amonio y suspensión de la diálisis.

  • Open Access

    Phosphated-based cathartic agent nephropathy in kidney trasplantation patient. Case report

    by Roberto Pineda, Alejandra Molano, Adriana Flórez, Roberto D`aChiardi, Benjamín Wancjer

    Nefropatía por agente catártico basado en fosfato de sodio en paciente renal trasplantado. Reporte de un caso